Losartan Potassium
Product Images NDC 66116-452

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 66116-452). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medvantx, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chem Structure For Losartan Potassium (F88c39fa Ed74 42f4 A886 C268daf8f3a6 01)

FDA Label Image

Figure 1 (F88c39fa Ed74 42f4 A886 C268daf8f3a6 02)

Figure 1 (F88c39fa Ed74 42f4 A886 C268daf8f3a6 02)
The text provides information about two medications, Atenolol and Losartan potassium, and a study on their efficacy in reducing risk. The study involved patients with a primary endpoint and show an adjusted risk reduction of 13% with a p-value of 0.021. The study was conducted over a period of 66 months with measurements taken every 6 months.*
FDA Label Image

Figure 2 (F88c39fa Ed74 42f4 A886 C268daf8f3a6 03)

Figure 2 (F88c39fa Ed74 42f4 A886 C268daf8f3a6 03)
The text is describing a comparison of two drugs, Atenolol and Losartan potassium, in terms of their effectiveness in reducing the risk of fatal or non-fatal stroke in patients. The analysis shows an adjusted risk reduction of 25% with a p-value of 0.001. The study was conducted over 66 months, with data collected at regular intervals from 6 months onwards.*
FDA Label Image

Figure 3 (F88c39fa Ed74 42f4 A886 C268daf8f3a6 04)

FDA Label Image

Figure 4 (F88c39fa Ed74 42f4 A886 C268daf8f3a6 05)

Figure 4 (F88c39fa Ed74 42f4 A886 C268daf8f3a6 05)
The text describes a clinical trial that compared the effect of Losartan Potassium and Placebo on patients with some specific event. The trial lasted for 24 months and the analysis shows a risk reduction of 16.1% in the Losartan group as compared to the Placebo group. The value of 'p' is 0.0022. The numbers 36 and 48 are also mentioned but it is unclear what they represent without further context.*
FDA Label Image

Losartan Potassium 50mg (F88c39fa Ed74 42f4 A886 C268daf8f3a6 06)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.